Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 4.85 CHF -6.73% Market Closed
Market Cap: 178.7m CHF
Have any thoughts about
Molecular Partners AG?
Write Note

Molecular Partners AG
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Molecular Partners AG
Capital Expenditures Peer Comparison

Comparables:
ADCT
ACIU
CRSP
BSLN
KURN

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Molecular Partners AG
SIX:MOLN
Capital Expenditures
-CHf794k
CAGR 3-Years
6%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Capital Expenditures
-$3.2m
CAGR 3-Years
-5%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Capital Expenditures
-CHf758k
CAGR 3-Years
33%
CAGR 5-Years
9%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Capital Expenditures
-$2.4m
CAGR 3-Years
69%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Capital Expenditures
-CHf1.2m
CAGR 3-Years
12%
CAGR 5-Years
-15%
CAGR 10-Years
2%
Kuros Biosciences AG
SIX:KURN
Capital Expenditures
-CHf849k
CAGR 3-Years
-45%
CAGR 5-Years
-56%
CAGR 10-Years
N/A

See Also

What is Molecular Partners AG's Capital Expenditures?
Capital Expenditures
-794k CHF

Based on the financial report for Jun 30, 2024, Molecular Partners AG's Capital Expenditures amounts to -794k CHF.

What is Molecular Partners AG's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-1%

Over the last year, the Capital Expenditures growth was 35%. The average annual Capital Expenditures growth rates for Molecular Partners AG have been 6% over the past three years , -1% over the past five years .

Back to Top